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Abstract
Background:  Cisplatin resistance is complex and involves several different mechanisms.
Employing cDNA microarray analysis, we have found that cisplatin resistant cells share the
common characteristic of increase in ribosomal proteins and elongation factors. We hypothesize
that in order to survive cisplatin treatment, cells have to synthesize DNA repair proteins,
antiapoptotic proteins and growth-stimulating proteins. Thus, by blocking the translation of these
proteins, one should be able to restore cisplatin sensitivity. We have studied the role of CCI-779,
an ester analog of rapamycin which is known to inhibit translation by disabling mTOR, in restoring
cisplatin sensitivity in a panel of cisplatin resistant cell lines. We have also determined the role of
CCI-779 in P-gp1 and MRP1 mediated resistance.
Results: Our data show that CCI-779 possess antiproliferative effects in both cisplatin sensitive
and resistant cell lines, but shows no effect in P-gp1 and MRP1 overexpressing cell lines.
Importantly, CCI-779 at 10 ng/ml (less that 10% of the growth inhibitory effect) can increase the
growth inhibition of cisplatin by 2.5–6 fold. Moreover, CCI-779 also enhances the apoptotic effect
of cisplatin in cisplatin resistant cell lines. In these resistant cells, adding CCI-779 decreases the
amount of 4E-BP phosphorylation and p-70S6 kinase phosphorylation as well as lower the amount
of elongation factor while cisplatin alone has no effect. However, CCI-779 can only reverse P-gp
mediated drug resistance at a higher dose(1 ug/ml).
Conclusion: We conclude that CCI-779 is able to restore cisplatin sensitivity in small cell lung
cancer cell lines selected for cisplatin resistance as well as cell lines derived from patients who failed
cisplatin. These findings can be further explored for future clinical use. On the other hand, CCI-
779 at achievable clinical concentration, has no growth inhibitory effect in P-gp1 or MRP1
overexpressing cells. Furthermore, CCI-779 also appears to be a weak MDR1 reversal agent. Thus,
it is not a candidate to use in MDR1 or MRP1 overexpressing cells.
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Introduction
Cisplatin and its analog carboplatin have significant anti-
tumor activity against a wide variety of solid tumors[1].
Furthermore, cisplatin also showed synergistic effect with
other chemotherapeutic agents and therefore has been
incorporated in many treatment regimens for solid
tumors [1]. Like other chemotherapeutic agents, resist-
ance to this drug is inevitable and often occurs after sev-
eral cycles of treatment. Several laboratories have studied
the mechanism(s) of cisplatin resistance in the past dec-
ades and many possible mechanism(s) have been identi-
fied [2-9]. These resistance mechanism(s) appears to fall
into four major categories. The first category involves
DNA damage/repair proteins. The second category
involves drug retention (increased influx or decreased
uptake). The third category involves increased drug inacti-
vation or prevention of drug to reach the DNA target. The
fourth category involves growth signaling via different
pathways or increase in antiapoptotic protein(s). Never-
theless, it is generally accepted that cisplatin resistance
most likely has multiple mechanisms and the mechanism
of resistance may differ depending on the cell types.
Therefore, overcoming cisplatin resistance may be diffi-
cult. We have developed two pairs of cisplatin resistant
small cell lung cancer cell lines and three cell lines derived
from patients who failed cisplatin, one from small cell
lung cancer (SCLC) and two from non small cell lung can-
cer (NSCLC). Using microarray analysis in our cisplatin
resistant cell lines as well as reviewing the available micro-
array data published in other laboratories, we have found
that the there are many gene(s) which are overexpressed
in these cisplatin resistant cell lines including those
involved in DNA repair, signal transduction, invasion and
metastasis, and antiapoptosis {for review see ref. [2]}.
While different cisplatin resistant cell lines often overex-
pressed different genes involved in DNA repairs and/or
signal transduction, antiapoptosis, a majority of cisplatin
resistant cells overexpress elongation factor alpha and
genes which are involved in ribosomal biogenesis. These
findings have led us to hypothesize that after DNA dam-
age by cisplatin, the surviving cells have to develop the
ability to generate repair proteins and/or survival proteins
to prepare for the next insult. Both ribosomal proteins
and elongation factor are essential for translational proc-
ess in protein synthesis. Thus, the common theme to sur-
vive cisplatin in these resistant cell lines is to increase
these mRNAs. Consequently, if ribosomal proteins and/or
elongation factor can be inhibited, one should be able to
restore cisplatin sensitivity. It is well known that mTOR
(mammalian target of rapamycin) also known as FRAP,
RAFT, or RAPT is important in regulating translation of a
set of mRNA which encode ribosomal proteins and elon-
gation factor [10-12]. All of these mRNAs possess a
sequence of pyrimidines at their extreme 5'end (TOP
mRNAs). Therefore, by inhibiting mTOR, one should be
able to restore cisplatin sensitivity. In this report, we have
investigated the possible role of a known mTOR inhibitor,
rapamycin and its ester analog CCI-779 [13,14] in restor-
ing cisplatin sensitivity.
It has been shown that the mTOR inhibitor, rapamycin,
can also modulate other forms of drug resistance such as
P-gp1 or MDR1 mediated drug resistance[15,16]. MDR1
is a well characterized form of drug resistance which is pri-
marily due to overexpression of an P-gp1 efflux pump
[17,18]. This efflux pump belong to ABC (ATP-binding-
cassette) transporter superfamily, and is capable of efflux-
ing many different chemotherapeutic agents, hence the
term multidrug resistance. The resistance is due to
decrease drug accumulation. Rapamycin has been shown
to be able to reverse this form of drug resistance by block-
ing the efflux pump[15]. Another similar form of multid-
rug resistance which is due to decrease drug accumulation
is the MRP1 mediated drug resistance. MRP1 also belongs
to the ABC transporter superfamily [19-21], however, this
efflux pump most likely transports the glutathione conju-
gated drug. In this report, we also investigated the role of
mTOR inhibitor in these two forms of multidrug
resistance.
Methods
Cell lines
SCLC1 was established from the bone marrow of SCLC
patient. SR-2 is the cisplatin resistant variant which was
generated by intermittent exposure to cisplatin. The char-
acteristics of these cell lines have been published previ-
ously [22]. All cell lines were maintained on RPMI media
supplemented with 10% FBS.
SCLC1R was generated by exposure of SCLC1 to rhodam-
ine-123 [23]. This cell line overexpresses P-gp and exhibits
16 fold resistance to doxorubicin, 70 fold resistance to
vinblastine and 5.3 fold resistance to VP-16, but not to
cisplatin.
SCLC1A overexpresses MRP1 and was selected by expo-
sure of SCLC1 to doxorubicin [24]. This cell line exhibits
33 fold resistance to doxorubicin, 10 fold resistance to VP-
16 and 42 fold resistance to vinblastine.
SCLCB was established from the supraclavicular lymph
node of a SCLC patient. The characteristics of this cell line
were previously published [25]. SCLCBC was generated
by exposure SCLC to cisplatin similar to SR-2. SCLCBC
exhibits 10 fold resistances to cisplatin, and 10 fold resist-
ances to carboplatin but not to oxaliplatin.
SCLCL  was established from the pleural effusion of a
SCLC patient who relapsed on VP-16 and cisplatin.
Unlike SCLC1 and SCLCB, this cell line grows as a floatingMolecular Cancer 2005, 4:25 http://www.molecular-cancer.com/content/4/1/25
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aggregate. SCLCL does not overexpress P-gp 1 or MRP1
and is positive for chromogranin.
NSCLCG  was established from a chest wall mass of a
patient with adenocarcinoma of the lung who failed cispl-
atin and taxotere. This cell line is positive for keratin and
does not overexpress P-gp1 and MRP1.
NSCLCW was established from the pleural effusion of a
patient with poorly differentiated adenocarcinoma of the
lung who failed gemcitabine + cisplatin, taxol + carbopla-
tin and irinotecan + oxaliplatin. This cell line does not
overexpress P-gp1 or MRP1.
All cell lines were maintained on RPMI supplemented
with 10% FBS.
Compounds
CCI-779 and rapamycin were kindly provided by Wyerh-
Ayrest. Cisplatin, carboplatin, oxaliplatin, VP-16, doxoru-
bicin and vinblastine were obtained from the hospital
pharmacy.
Growth Inhibitory effect
1 × 106 cells were seeded onto 24-well plates and allowed
8 hr. for attachment. Various concentrations of rapamycin
or its analogs CCI-779 or other chemotherapeutic drugs
listed above were added to each well. Each concentration
was performed in duplicate. After 72 hr. exposure, viable
cells were counted in the presence of 0.2% trypan blue.
The growth inhibitory effect (ID50) was determined by
plotting the number of viable cells as a percentage of con-
trol against the compound concentration[26]. The growth
inhibitory effect was performed after cells were kept in
drug free media for 14 days.
Assay for Apoptosis by Annexin V
Cells were treated with cisplatin with and without CCI-
779 for 24 hrs. and then assay for apoptosis using
Annexin V-FITC Apoptosis Detection kit (BD Bioscience).
The kit includes annexin V conjugated to FITC and pro-
pidium iodide. For each sample, 105 or 106 cells were col-
lected, washed in PBS and gently suspended in 100 µL of
binding buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 5
mM KCl, 1 mM MgCl2, 1.8 mM CaCl2) containing 0.25 µg
annexin V-FTIC. Incubation lasted 15 min in the dark at
room temperature. Finally, cells were washed and sus-
pended in the binding buffer with 5 µg propidium iodide
and analyzed with Coulter XL flow cytometer. At least
10,000 cells were counted per analysis.
Westernblot Analysis of mTOR
Cells were lysed with RIPA buffer (10 mMTris pH7.4 100
mM NaCl, 1 mM EDTA, 20 mM Na4P2O7, 2 mM Na3VO4
10%, 0.5% deoxycholate, 1 mM PMSF) and protease
inhibitor cocktail from Sigma and passed several times
through a 23G needle, and centrifuged. The total protein
was separated on 8% SDS-PAGE, transferred onto mem-
brane and immunoblot with rabbit polyclonal antibody
to mTOR (purchased from Upstate) and detected by
chemiluminescence.
Westernblot Analysis of 4E-BP
The method described by Gingra et.al. was used [27]. Cells
were seeded at 1 × 105 cells /ml onto 100 mm dishes,
allowed overnight for attachment, then treated with vari-
ous doses of cisplatin, with and without CCI-779. At 24
hrs, cells were harvested by scraping with RIPA buffer and
protease inhibitor cocktail (purchased from Sigma). Lysis
was completed by passing the cells through a 25 G needle.
To bind elF-4E, 25 ul of 7methyl-GTP Sepharose was
added to the lysates and incubated overnight at 4°C. The
complexes were collected by centrifuge, washed with lysis
buffer, then dissociated from sepharose by adding 50 ul of
SDS-PAGE loading buffer, heated to 95°C then separated
by SDS-PAGE, probed with 4E-BP antibody (purchased
from Cell Signaling) and detected by chemiluminescence.
Westernblot Analysis for p70-S6 Kinase
This is similar to analyses of 4E-BP. Cells were seeded at 1
× 105 onto 100 mm dishes, exposed to cisplatin alone or
in combination with CCI-779 overnight, lysed with RIPA
buffer and then separated by SDS-PAGE. The membrane
was probed with phospho-p70-S6 kinase antibody pur-
chased from Cell Signaling (phospho-thre.389) and
detected by chemiluminescence. This is a mouse mono-
clonal antibody which recognizes phospho-p70 S6
kinase.
Westernblot Analysis for elongation factor α
Cisplatin resistant cells (SR-2 and SCLCBC) were treated
with cisplatin or CCI-779 or combination of CCI-779 and
cisplatin for 24 hours. Protein extracts were obtained and
separated by SDS-PAGE and probed with anti-EF-1α  mon-
oclonal antibody (purchased from Upstate) and detected
with chemiluminescence. This antibody detects a 53 kDa
protein.
Results
Growth Inhibitory Effect of rapamycin and CCI-779
Table 1 shows the result of growth inhibitory effect of
rapamycin and CCI-779 in a panel of parental and resist-
ant SCLC lines. Both CCI-779 and rapamycin are equally
active in parental cell lines as well as their cisplatin resist-
ant variants. Furthermore, CCI-779 is also active in cell
lines which were established from patients who failed cis-
platin containing regimens with the ID50 ranging from
0.1–0.5 ug/ml. In contrast, CCI-779 and rapamycin have
no activity in P-gp1 or MRP1 overexpressing cell lines with
the ID50 of 6.9 and 7.5 ug/ml, respectively. This is notMolecular Cancer 2005, 4:25 http://www.molecular-cancer.com/content/4/1/25
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surprising, since the structure of rapamycin suggest that it
may be a P-gp substrate [28].
Growth Inhibitory effect of CCI-779 in combination with 
cisplatin
Since CCI-779 is equally or slightly better than rapamycin
in terms of growth inhibitory effects and is currently in
clinical trial, we have further investigated whether the
addition of CCI-779 can indeed increase cisplatin sensi-
tivity, We have studied growth inhibitory effect of cispla-
tin in the presence of 10 ng/ml of CCI-779. At this dosage,
the growth inhibitory effect is less than 10%. The results
are shown in table 2. CCI-779 is able to reduce the ID50
of cisplatin to 3–6 times in all cisplatin resistant cell lines.
However, CCI-779 does not alter the ID50 in the parental
line. Thus, it appears that CCI-779 can restore cisplatin
sensitivity in otherwise cisplatin resistant cells. We further
investigated whether CCI-779 can completely reverse cis-
platin resistance. SR.2 and SCLCBC were treated with the
cisplatin ID50 of sensitive cells (0.15 ug/ml in SCLC1 and
0.25 ug/ml in SCLCBC) and various concentrations of
CCI-779. Our results indicate that CCI-779 at 0.03 ug/ml
can completely reverse cisplatin resistance in both SR-2
and SCLCBC.
We have further investigated whether combination of
CCI-779 with cisplatin can also induce apoptosis in cispl-
atin resistant cells. The results are shown in fig 1. Cisplatin
at 6 ug/ml cannot induce apoptosis in these resistant cells,
while at a higher dose (10 ug/ml), the apoptotic effect is
small but discernable. However, when CCI-779 (150 ng)
was added to cisplatin, the effect is seen at 6 ug/ml of cis-
platin and increases at 10 ug/ml. Thus, our data clearly
shows that the addition of CCI-779 to cisplatin in these
resistant cells not only augments the growth inhibitory
effect, but also the apoptotic effect of cisplatin. Similar
results were also obtained with SCLCBC cell lines. It is
noteworthy that, CCI-779 alone at 300 ng/ml did not
induce apoptosis (data not shown) in both cisplatin sen-
sitive cells (SCLC1 and SCLCB).
The effect of CCI-779 in reversing doxorubicin resistance 
in P-gp1 and MRP1 overexpressing cells
It has been shown that rapamycin can block P-gp efflux
pump [15,16], but is less potent than cyclosporin. We
have studied whether CCI-779 can block P-gp and MRP1
efflux pump and consequently increased doxorubicin sen-
sitivity in these P-gp1 and MRP1 overexpressing cells. Our
data demonstrated that at 10 ng/ml of CCI-779, there is
no effect on the ID50 of doxorubicin in both P-gp1 and
MRP1 overexpressing cells. However, at 1 ug/ml CCI-779
is able to decrease the ID50 from 0.04 to 0.009 ug/ml. The
data are summarized in table 3. Thus, our data suggest
that CCI-779 is a weak P-gp blocker compared to those
previously reported for rapamycin.
MTOR expression by westernblot analysis
It is known that mTOR is a target of CCI-779. It is possible
that sensitivity to mTOR inhibitor may be related to
mTOR levels. We have studied mTOR expression in the
cisplatin sensitive and resistant cells. The result is shown
in fig 2. There are no discernable differences in mTOR lev-
els in these cell lines.
4E-BP phosphorylation
It is well known that mTOR phosphorylates 4E-BP and
releases its binding from eIF-4E. This results in translation
initiation. Inhibition of mTOR will prohibit its ability to
phosphorylate 4E-BP and thereby inhibit the translation
process. We have studied 4E-BP phosphorylation in
SCLC1/SR2, SCLCB/SCLCBC. Our results are shown in fig
3. Cisplatin does not affect 4E-BP phosphorylation in cis-
platin resistant cell lines. However, the addition of CCI-
779 inhibits this process. We have tested two different
doses of CCI-779 (150, and 300 ng/ml), our data indicate
that 150 ug/ml is as efficient as 300 ug/ml in inhibiting
Table 1: Growth inhibitory effect of Rapamycin and CCI-779 (ID50)
SCLC1 SR-2 SCLCB SCLCBC SCLCL SCLCR SCLCA NSCLCW NSCLCG
Rapamycin ug/ml 0.66 ± 0.1 0.1 ± .0.05 0.05 ± 0.02 0.09 ± 0.03 0.2 ± 0.006 >1 >1 ND* ND*
CCI-779 ug/ml 0.07 ± 0.02 0.06 ± 0.01 0.04 ± ..0.01 0.05 ± 0.02 0.3 ± 0.1 6.9 ± 2.4 7.5 ± 1.5 0.3 ± 0.1 0.5 ± 0.2
*ND = not done. The ID50 represent the average of two experiments, each experiment done in duplicate.
Table 2: Growth inhibitory effect of Cisplatin (ID50) with and 
without CCI-779
Cisplatin (ug/ml) Cisplatin (ug/ml)+ CCI-779
SCLC1 0.15 ± 0.05 0.18 ± 0.02
SR-2 2.52 ± 0.51 0.45 ± 0.03
SCLCB 0.25 ± 0.12 0.14 ± 0.02
SCLCBC 2.57 ± 0.23 0.55 ± 0.04
SCLCL 0.95 ± 0.08 0.3 0 ± 0. 05
NSCLCW 1.2 ± 0.07 0.28 ± 0.04
NSCLCG 1.5 ± 0.5 0.4 ± 0.07Molecular Cancer 2005, 4:25 http://www.molecular-cancer.com/content/4/1/25
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Apoptosis assay using annexin-V by FACS analysis in cisplatin resistant cell line (SR-2) Figure 1
Apoptosis assay using annexin-V by FACS analysis in cisplatin resistant cell line (SR-2). Cells were treated with cisplatin alone 
or in combination with 0.15 ug of CCI-779. Left panels are dual staining for propidium iodide uptake and annexin-VFITC, Right 
panels are corresponding distribution of annexin VFITC staining in populations of cells. 1A: control. 1B: SR-2 treated with 6 ug of 
cisplatin (No annexin VFITC was detected) 1C: SR-2 treated with 6 ug of cisplatin+CCI-779 (small peak of annexin VFITC was 
detected) 1D: SR-2 treated with 10 ug of cisplatin (a peak of annexin VFITC was detected) 1E: SR-2 treated with 10 ug of cispla-
tin+CCI-.779 (a large peak of annexin VFITC was detected) Note: CCI-779 alone at 0.15 and 0.3 ug/ml did not induce apoptosis 
(data not shown).
A:Control
B:Cis 6ug
C:Cis6ug+CCI-779
D:Cis 10ug
E:Cis10ug+CCI-779
A:Control
B:Cis 6ug
C:Cis6ug+CCI-779
D:Cis 10ug
E:Cis10ug+CCI-779Molecular Cancer 2005, 4:25 http://www.molecular-cancer.com/content/4/1/25
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4E-BP phosphorylation. We have further reduced the dose
to 100 ng and the effect on 4E-BP phosphorylation are
similar to 150 ng/ml(data not shown). In contrast, in sen-
sitive cells, the phosphorylation of 4E-BP decreased after
the addition of cisplatin alone (fig 3, panel A&C). This
effect is only slightly enhanced by CCI-779. These results
correspond with the growth inhibitory effect illustrated in
table 2 which showed that CCI-779 decreased the ID50 in
cisplatin resistant cells but has only minimal effect on sen-
sitive cells.
P-70S6 kinase phosphorylation
It is well known that CCI-779 decreases p-70 S6 kinase
activity by inhibiting its phosphorylation.. We have deter-
mined the levels phospho-P-70 S6 kinase by westernblot
analysis. Our results are shown in fig 4. Cisplatin at 0.1
ug/ml or 10 ug/ml did not affect the phosphorylation in
two cisplatin resistant cell lines, however, the phosphor-
ylation decreased after adding CCI-779. In contrast, in
parental cells (SCLC1 and SCLCB), the levels of phospho-
p-70 S6 kinase is decreased after adding cisplatin at 0.1
ug/ml and decreased slightly after the addition of CCI-
779(data not shown). These findings are similar to the
phosphorylation of 4E-BP.
Assay for elongation factor alpha (eEF1-α )
It has been shown that rapamycin can selectively inhibit
translation of mRNA encoding elongation factor alpha. In
addition, our cisplatin resistant cell lines also overexpress
elongation factor α  (fig 5, panel A). We have examined
whether CCI-779 has effect on elongation factor alpha.
The data are shown in fig 5 (panel B&C). Cisplatin at 10
ug/ml has no effect on eEF-1 α  in these resistant cell lines.
However, after adding CCI-779, the eEF-1 α  is much less.
Discussion
The mechanisms of cisplatin resistance have been studied
for the last several decades. To date, there is no effective
pharmacological manipulation to overcome this form of
complex resistance. In this report, we have found that
mTOR inhibitor (CCI-779) is able to restore cisplatin sen-
sitivity. This is most likely due to the fact that mTOR
inhibitor can down regulate protein synthesis. mTOR reg-
ulates translation of proteins which are involved in cell
cycle progression and cell growth [12,29-32]. The two best
characterized downstream targets of mTOR are two fami-
lies of proteins that control translation, the ribosomal
protein S6 kinase (S6K) and the eukaryotic initiation fac-
tor eIF4E binding protein (4E-BP)[12,33-35]. S6K1
(p70S6 kinase) phosphorylates S6 which controls the
translation of mRNA that possesses an unusual oligopyri-
midine tract at its transcription starting site termed 5'TOP.
These 5'TOP mRNAs encode major components of pro-
tein synthesis machinery (ribosomal protein and elonga-
tion factor). Another downstream target of mTOR is eLF-
4E binding protein 4E-BP. eIF-4E is known to control
translation of mRNA with secondary structure (often GC
rich)[36]. These mRNAs are known to encode proteins
related to proliferation. In this study, we have shown that
in cisplatin resistant cells the phosphorylation of 4E-BP is
not affected by cisplatin alone, but decreased after adding
CCI-779 which indicates that CCI-779 can block the
translational initiation. Similar results were obtained for
the phosphorylation of p-70 S6 kinase. In contrast, in
parental (cisplatin sensitive cells), cisplatin alone is able
to decrease the phosphorylation of both 4E-BP and p-
70S6 kinase, although this effect is slightly augmented
with the addition of CCI-779. These results correspond
with our growth inhibitory findings which show that the
addition of CCI-779 only slightly augments the growth
inhibitory effect of cisplatin in sensitive cells. The ability
of cisplatin to inhibit 4E-BP and p-70 S6 kinase in cispla-
tin sensitive cells has been reported by others [37]. The
exact mechanism is not known. Nevertheless, this mode
of action appears to diminish in cisplatin resistant cell
lines, and these cells are able to readily turn on the trans-
lational machinery. Overall, our findings support our
Table 3: Growth inhibitory effect of Doxorubicin (ID50) with and without CCI-779
DOX (ug/ml) DOX+0.01 ug CCI-779 DOX+1 ug CCI-779
SCLCA 0.09 ± 0.02 0.07 ± 0.01 0.08 ± 0.02
SCLCR 0.042 ± 0.01 0.058 ± 0.02 0.009 ± 0.005
Westernblot analysis of mTOR in Lane1: SCLCB, Lane 2:  SCLCBC Figure 2
Westernblot analysis of mTOR in Lane1: SCLCB, Lane 2: 
SCLCBC. Lane 3: SR-2, Lane 4: SCLC1. Note: there are no 
differences in mTOR levels in these 4 cell lines.
mTOR
1234Molecular Cancer 2005, 4:25 http://www.molecular-cancer.com/content/4/1/25
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Westernblot analysis of 4E-BP phosphorylation in parental and cisplatin resistant small cell lung cancer cell lines Figure 3
Westernblot analysis of 4E-BP phosphorylation in parental and cisplatin resistant small cell lung cancer cell lines. A: SCLC1 
(parental line) was treated with 0.1 ug/ml of cisplatin alone, CCI-779 alone or in combination. Lane1: control (untreated cells) 
which showed high amount of phosphorylated 4E-BP. Lane 2: SCLC1 treated with 0.1 ug/ml of cisplatin which showed a 
decrease in the amount of phosphorylated 4E-BP, lane 3&4: SCLC1 treated with 150 ng/ml of CCI-779 alone and CCI-779 with 
cisplatin 0.1 ug/ml respectively. Both showed comparable amount of phosphorylated 4E-BP and are less than control cells and 
or cells treated with cisplatin alone. B: 4E-BP phosphorylation in SR-2 (cisplatin resistant cell line derived from SCLC1) after 
treatment with cisplatin with and without CCI-779. Lane 1: Control untreated cells which showed an abundant amount of 
phospho-4E-BP, lane 2, 3, and 4: SR-2 treated with 5,10 and 0.1 ug/ml of cisplatin. The amount of phospho-4E-BP are not 
affected by cisplatin at low dose, but slightly decreased at high dose. Lane 5,6 SR-2 treated with CCI-779 at 150 ng and 300 ng/
ml respectively. Predominantly unphosphorylated 4E-BP is seen, Lane 7&8: SR-2 treated with 150 ng/ml of CCI-779 combined 
with cisplatin 5 ug and 10 ug/ml respectively. Small amounts of phosphorylated 4E-BP are seen and much less than those with 
cisplatin alone (lane 2,3&4). C:4E-BP phosphorylation in SCLCB(parental line). Lane 1: Control untreated cells which showed 
an abundant amount of phospho-4E-BP, lane 2: SCLCB treated with 0.1 ug/ml of cisplatin showed a decrease amount of phos-
pho-4E-BP. lane 3 & 4 SCLCB treated with 150 ng/ml of CCI-779 alone and CCI-779 150 ng/ml with 0.1 ug/ml of cisplatin 
respectively. Both showed comparable amount of phospho-4E-BP and is slightly less than cisplatin alone. D: 4E-BP phosphoryla-
tion in SCLCBC (cisplatin resistant cells). Lane 1,2,3: SCLCBC treated with CCI-779 150 ng/ml combined with cisplatin at 1,5 
and 10 ug/ml of cisplatin respectively. The amount of phospho-4E-BP is minimum and predominantly unphosphorylated form, 
lane 4&5 SCLCBC treated with CCI-779 at 150 ng and 300 ng/ml, only unphosphorylated 4E-BP predominate. Lane 6,7,8 
SCLCBC treated with 10,5 and 1 ug/ml of cisplatin respectively. The amount of phospho4E-BP are similar to the control cells. 
Lane 9. Control untreated cells. Actin is used as control for protein loading for all cell lines
4E-BP
Phospho4E-BP
actin
4E-BP
Phospho4E-BP
actin
A
12 3 4
B
actin
C
Phospho-4E-BP
4E-BP
D
actin
1 23 4567 8
Phospho4E-BP
4E-BP
1 23 4567 8
Phospho4E-BP
4E-BP
123 4
Phospho-4E-BP
4E-BP
123 4
Phospho-4E-BP
4E-BP
actin actinMolecular Cancer 2005, 4:25 http://www.molecular-cancer.com/content/4/1/25
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notion that the reason why cisplatin resistant cell lines up
regulated the mRNA encoding for ribosomal protein and
elongation factors is due to the fact that these resistant
cells have to turn on the protein synthesis machinery in
order to survive. Consequently, by inhibiting the protein
translational machinery using CCI-779, cisplatin resist-
ance can be overcome. Furthermore, our preliminary
results also show that CCI-779 can inhibit the synthesis of
DNA repair proteins, cell cycle protein as well as telomer-
ase which further support our hypothesis. Importantly,
these findings also can be applied to de-novo cisplatin
resistant cell lines derived from patients who failed treat-
ment (SCLCL, NSCLCW and NSCLCG). The ID50 of cis-
platin was decreased by 3–4 folds after CCI-779. The
concentration we used to overcome cisplatin resistance is
low (10 ng/ml) and is clinically achievable. [38,39] These
findings can have significant clinical implication for
future use of mTOR inhibitors to overcome cisplatin
resistance.
It has been previously demonstrated that rapamycin can
reverse MDR1 mediated drug resistance [15]. Further-
more, both P-gp1 and MRP1 mediated drug resistance
have been reported in lung cancer [40-42]. Thus, we have
also investigated the possible antitumor activity as well as
Westernblot analysis of phospho-P70S6kinase in cisplatin  resistant cells Figure 4
Westernblot analysis of phospho-P70S6kinase in cisplatin 
resistant cells. A: SR-2 cells. Lane 1. SR-2 treated with cispla-
tin 10 ug/ml and CCI-779 150 ng/ml, lane 2: SR-2 treated 
with CCI-779 at 150 ng/ml. Both 1&2 showed only minimal 
amount of phospho-p70S6kinase. Lane 3&4 SR-2 treated with 
cisplatin at 0.1 and 10 ug/ml., cisplatin does not affect the 
amount of phospho-p70S6kinase and showed similar inten-
sity to control cells. Lane 5: control untreated cells. B. 
SCLCBC cells. Lane 1: Control untreated cells, lane 2&3 
SCLCBC treated with cisplatin at 0.1 and 10 ug/ml respec-
tively. Similar amounts of phospho-p70S6kinase were seen. 
Lane 4 SCLCBC treated with cisplatin 10 ug/ml and CCI-779 
150 ng/ml. The amount of phosphor-p70S6kinase is less. Lane 
5 SCLCBC treated with CCI-779 at 150 ng/ml. No signal 
intensity for p-70S6kinase was seen. Actin was used as con-
trol for protein loading.
12 3 4 5
Phospho-P70S6K
A
Actin
12 3 45
Phospho-P70S6K
B
Actin
Westernblot analysis of eEF-1α Figure 5
Westernblot analysis of eEF-1α . A eEF-1α  in sensitive and 
resistant cells. Lane 1. SCLCB, lane 2: SCLCBC, lane 3: SR-2, 
lane 4: SCLC1. The signal intensity of the resistant cell line 
SCLCBC and SR-2 are much greater than their sensitive cells 
SCLCB and SCLC1 counterpart. B eEF-1α  in SR-2 cell line. 
Lane 1: control, lane 2&3: SR-2 treated with 0.5 and 10 ug/ml 
of cisplatin respectively. Similar signal intensity are seen com-
pared to control, lane 4&5: SR-2 treated with 10 ng and 50 
ng/ml of CCI-779 respectively. There is no change in signal 
intensity of eEF-1α  at 10 ng of CCI-779, but decreased after 
exposure to 50 ng/ml of CCI-779, lane 6: SR-2 treated with 
10 ug/.ml of cisplatin with CCI-779 50 ng/ml, the signal inten-
sity also less and similar to those treated with CCI-779 alone. 
C eEF-1α  in SCLCBC. Lane 1: control, lane 2&3 SCLCBC 
treated with 0.5 ug and 10 ug/ml of cisplatin respectively. 
Similar signal intensity of eEF-1α  is seen compared to con-
trol, lane 4&5: SR-2 treated with 10 ng and 50 ng/ml of CCI-
779 respectively, there is no changes in signal intensity at 10 
ng/ml of CCI-779, but decreased at 50 ng/ml of CCI-779, lane 
6 SCLCBC treated with 10 ug/ml of cisplatin with CCI-779 
50 ng/ml. The signal intensity is less and similar to those 
treated with CCI-779 alone.
eEF-1α A
12 3 4
eEF-1α
B
actin
eEF-1α C
actin
12 345 6 12 345 6
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reversal activity of CCI-779 in P-gp1 and MDR1 overex-
pressing cell lines. Our results demonstrated that both
CCI-779 and rapamycin have no antitumor activity in P-
gp1 or MRP1 overexpressing cell lines. It is possible that
both rapamycin and CCI-779 are recognized by both P-
gp1 and MRP1. This is not surprising since it has been
reported that rapamycin can be transported by P-gp in
renal proximal tubule [43]. We have also found that CCI-
779 is a weak reversal agent when compared with those
reported for rapamycin. CCI-779 at 1 ug/ml (1 uM) can
only decrease the ID50 of doxorubicin by 4.5 fold whereas
rapamycin at 1 uM can decrease the ID50 of daunorubicin
by 10 fold [15]. This may be due to the fact that CCI-779
is more water soluble and thus is less effective as reversal
agent [44]
Conclusion
We conclude that CCI-779 is able to restore cisplatin sen-
sitivity in small cell lung cancer cell lines which were
selected for cisplatin resistance aswell as cell lines derived
from patients who failed cisplatin. The most likely mech-
anism is due to inhibition of translation of proteins which
are involved in cisplatin resistance. These findings should
be further explored in the clinic. However, CCI-779 has
no antitumor activity in P-gp1 and MRP1 overexpressing
cell lines. Moreover, CCI-779 can only partially reverse P-
gp1 at a higher dose (1 ug/ml). Therefore, CCI-779 is not
a good candidate to use in MDR1 or MRP1 overexpressing
cells.
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